Hatteras Venture Partners — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.
BiotechHealthtechDurham, US
Aravind Asokan(Director)Mavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)Patrick Ritschel(Executive Officer, Director, Promoter)
Board seatClay ThorpMike Dial· per SEC Form D
Co-investorsPontifax Venture Capital
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatClay Thorp· per SEC Form D
Co-investorsAtlas VentureLightstone VenturesVida VenturesLongwood Fund
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inKevin Lalande(Director)inRichard Simon(Director)
Co-investorsBonaventure Equity, LLCIter InvestmentsMission BiocapitalRoute 66 VenturesService Provider CapitalSante Health Ventures
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)Marcel Frenkel(Executive Officer, Director)Damien Petty(Director)Jia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersAlexandriaHatteras+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.